BELMONT, W.Va. (WTAP) - One local family is sharing the story of a brave boy who battles cancer. 8-year-old Negan Castleberry, according to his mom, Jennifer Castleberry, was just a normal child ...

Acute myeloid leukemia (AML), the most common hematologic malignancy, is characterized by the uncontrolled proliferation of highly heterogeneous hematopoietic stem and progenitor cells, leading to ...

While lineage switching has been historically associated with conventional chemotherapy regimens, emerging evidence confirms its occurrence following blinatumomab treatment, with the most common ...

Marseille, France, July 21, 2025 – ImCheck Therapeutics today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized ...

The Treasury's financial crime agency delayed enforcement of a variety of Bank Secrecy Act requirements for investment advisors in order to gain time to revise and tailor regulations.

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, M.D., Ph.D., the principal investi ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with certain subtypes of acute myeloid leukemia (AML).

A groundbreaking drug, blinatumomab, is transforming leukemia treatment, offering new hope for patients like 4-year-old Madi Seivert.

SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates.